U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf

Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Bleomycin has antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).

CNS Activity

Curator's Comment: Bleomycin does not cross the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
PubMed

PubMed

TitleDatePubMed
Ultrastructural study of the effect of bleomycin A2 on the nucleolus and its possibly related cytoplasmic constituents in Novikoff hepatoma cells.
1975 Feb
Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity.
1983 May
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.
1985 Dec 15
Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy: a report of a case and a review of the literature.
1989
Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.
1990 Jul
CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis.
2003 Dec 21
Dual roles of IL-4 in lung injury and fibrosis.
2003 Feb 15
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
2004 Dec
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.
2005 Dec
[Rat alveolar type II injured by bleomycin].
2005 Feb
Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats.
2005 Jan 15
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.
2006 Nov 21
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
2007 Feb 10
Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?
2007 Jun
FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.
2007 Nov
Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice.
2008 Sep 20
Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats.
2010 Aug
XRCC1 deficiency sensitizes human lung epithelial cells to genotoxicity by crocidolite asbestos and Libby amphibole.
2010 Dec
Influence of p53 expression on sensitivity of cancer cells to bleomycin.
2010 Jul-Aug
Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells.
2011 Feb
Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats.
2012 Dec 16
The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals.
2012 Jan
Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2.
2013 Sep 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bleomycin can be given intramuscularly, or subcutaneously in Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease and as a single dose bolus intrapleural injection (60 units) in Malignant Pleural Effusion.
The main components of Bleomycin for Injection are bleomycins A2 and B2. Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma - 0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Route of Administration: Other
In Vitro Use Guide
Purified nucleolar DNA was markedly degraded at a concentration of 13 ug/ml by bleomycin A2; bleomycin concentrations 20-30 times greater were required to degrade nucleoplasmic DNA. Whole nuclear DNA was degraded to only a small extent at 13 ug/ml but was markedly degraded at higher bleomycin concentrations.
Name Type Language
BLEOMYCIN
HSDB   INN   VANDF   WHO-DD  
INN  
Official Name English
Bleomycin [WHO-DD]
Common Name English
BLEOMYCIN HYDROCHLORIDE [JAN]
Common Name English
BLEOMYCIN [VANDF]
Common Name English
BLENAMAX
Brand Name English
NSC-125066
Code English
BLEOMYCINS
MI  
Common Name English
bleomycin [INN]
Common Name English
BLEOMYCINS [MI]
Common Name English
BLEOMYCIN [IARC]
Common Name English
BLEOMYCIN [HSDB]
Common Name English
BLEOMYCIN HEXAL
Brand Name English
BLEO
Brand Name English
BLEOCIN
Brand Name English
BLEOMYCINS [IARC]
Common Name English
MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548499
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
WHO-VATC QL01DC01
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
NCI_THESAURUS C2311
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
NDF-RT N0000180854
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
FDA ORPHAN DRUG 118498
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
FDA ORPHAN DRUG 326510
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
WHO-ATC L01DC01
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
Code System Code Type Description
DRUG CENTRAL
4742
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
CHEBI
3139
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
LACTMED
Bleomycin
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
RXCUI
1622
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY RxNorm
EVMPD
SUB00842MIG
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
HSDB
3208
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
ChEMBL
CHEMBL3039590
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
NSC
125066
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
MESH
D001761
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
EPA CompTox
DTXSID1030862
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
CAS
11056-06-7
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
NCI_THESAURUS
C313
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
FDA UNII
40S1VHN69B
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
MERCK INDEX
M2589
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB00290
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
WIKIPEDIA
BLEOMYCIN
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
INN
2721
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
DAILYMED
40S1VHN69B
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
All of the following components must be present:
Definition References